We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Tools
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Ondine Biomedical Inc. | LSE:OBI | London | Ordinary Share | CA68234M2058 | COM SHS NPV (CDI) |
| Price Change | % Change | Share Price | Shares Traded | Last Trade
|
|
|---|---|---|---|---|---|
| 1.65 | 18.64% | 10.50 | 566,184 | 15:46:36 |
| Bid Price | Offer Price | High Price | Low Price | Open Price | |
|---|---|---|---|---|---|
| 10.00 | 11.00 | 10.50 | 8.85 | 8.85 | |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Biological Pds,ex Diagnstics | CAD 1.79M | CAD -16.27M | CAD -0.0836 | -1.26 | 20.43M |
| Last Trade Time | Trade Type | Trade Size | Trade Price | Currency |
|---|---|---|---|---|
| 16:01:36 | O | 95,883 | 10.42 | GBX |
| Date | Time | Source | Headline |
|---|---|---|---|
| 04/12/2023 | 17:33 | ALNC |  TRADING UPDATES: 600 Group disposal and funding talks continue |
| 04/12/2023 | 13:28 | UKREG | Ondine Biomedical Inc. Close of Bookbuild |
| 01/12/2023 | 20:54 | ALNC | TRADING UPDATES: Legal boost for Dialight; VSA in Lush-related claim |
| 01/12/2023 | 18:13 | UKREG | Ondine Biomedical Inc. Update. Re investor-led financing |
| 30/11/2023 | 18:40 | UKREG | Ondine Biomedical Inc. Ondine announces investor-led financing |
| 16/11/2023 | 14:26 | ALNC | EARNINGS AND TRADING: Tatton profit up; Mycelx to miss expectations |
| 16/11/2023 | 07:00 | UKREG | Ondine Biomedical Inc. Photodisinfection recommended as Standard of Care |
| 31/10/2023 | 13:22 | ALNC | Ondine Biomedical jumps as Alberta Health Services expands Steriwave |
| 31/10/2023 | 09:00 | RNSNON | Ondine Biomedical Inc. Steriwave use expanded following successful pilot |
| 23/10/2023 | 10:14 | ALNC | Ondine Biomedical shares soar as Steriwave shown to reduce infection |
Ondine Biomedical (OBI) Share Charts1 Year Ondine Biomedical Chart |
|
1 Month Ondine Biomedical Chart |
Intraday Ondine Biomedical Chart |
| Date | Time | Title | Posts |
|---|---|---|---|
| 04/12/2023 | 19:35 | Steriwave is on track to be approved in the US in 2024 | 149 |
| 04/12/2023 | 19:31 | O B I | 369 |
| 31/8/2023 | 11:28 | Potential | 8 |
| Trade Time | Trade Price | Trade Size | Trade Value | Trade Type |
|---|---|---|---|---|
| 16:32:13 | 10.42 | 95,883 | 9,991.01 | O |
| 16:01:38 | 10.22 | 59,288 | 6,059.23 | O |
| 15:59:13 | 10.89 | 5,611 | 611.04 | O |
| 15:58:30 | 10.89 | 9,100 | 990.99 | O |
| 15:52:44 | 10.90 | 18,238 | 1,987.94 | O |
| Top Posts |
|---|
Posted at 04/12/2023 08:20 by Ondine Biomedical Daily Update Ondine Biomedical Inc. is listed in the Biological Pds,ex Diagnstics sector of the London Stock Exchange with ticker OBI. The last closing price for Ondine Biomedical was 8.85p.Ondine Biomedical currently has 194,584,524 shares in issue. The market capitalisation of Ondine Biomedical is £20,431,375. Ondine Biomedical has a price to earnings ratio (PE ratio) of -1.26. This morning OBI shares opened at 8.85p |
Posted at 04/12/2023 18:28 by z1co Distraction's are norm for this type of a troll.Why has the share price increased today by more than 18%? Very strong demand for the shares. 2024 could well be a very exciting year for this little company and it's shareholders; |
Posted at 04/12/2023 15:42 by z1co The share price went to over 15p twice and fell due to funding concerns and now that the funding is all sorted the shares will at least reach 15p and possibly a lot more higher and very soon. |
Posted at 10/11/2023 11:59 by z1co Yeh iv'e heard that from you before as well for someone to pay advfn £10 just to post on a thread that makes you a proper troll.Get your monies worth while the share price is low because you'll be long gone when the share price starts to rise strongly. a troll like you will never change. I expect the company to announce more hospital take ups as well pilots very soon.Phase 3 trials will also be starting very soon. Plenty of positive news to look forward to. Very relaxed holding the shares |
Posted at 09/11/2023 22:19 by z1co Grandpa beeksy this is for to read and try to understand if you can:Steriwave shown to reduce resistant bacteria by >99.9% -- New research presented by Ondine shows that Steriwave photodisinfection reduces antibiotic-resistant bacteria by more than 99.9% without generating resistance. -- The research suggests that photodisinfection is a viable alternative to antibiotics. Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) is today presenting new research showing that Steriwave (R) photodisinfection reduced antibiotic-resistant bacteria by more than 99.9%. The in vitro study, which is being presented today at the IP2023 Annual conference taking place in Liverpool 17-19 October 2023, indicates that photodisinfection is likely to play an important role in strategies for combatting antimicrobial resistance (AMR). The controlled study evaluated the efficacy of Ondine's Steriwave (R) photodisinfection against Gram-negative and Gram-positive multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria with novel antibiotic resistance factors. All of the bacterial strains used in the study exhibited resistance against some of the most commonly prescribed antibiotic classes, including penicillin, tetracyclines, quinolones and carbapenems. The results of the study showed that treatment with photodisinfection resulted in >99.9% reduction of viable bacteria compared to the control, regardless of the antibiotic susceptibility of the bacteria. The authors concluded that photodisinfection is likely an important adjunct to AMR strategies in the future and that further clinical studies are warranted. Antimicrobial resistance (AMR) remains a major public health concern, causing 33,000 deaths in Europe annually ([1]) which is projected to rise to over 10 million globally by 2050. ([2]) There are widespread multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections across the world which are mainly caused by Gram-negative bacteria including Enterobacteriaceae and P. aeruginosa AMR bacteria ([3]) (, [4]) and Gram-positive bacteria such as Staphylococcus spp. ([5]) Steriwave has been found to be highly effective against all these pathogens. Photodisinfection uses a photosensitizer and a specific wavelength of light to trigger photochemical reactions that produce reactive oxygen species. These reactive oxygen species are lethal to a broad spectrum of microbes, including bacteria, fungi, and viruses. Importantly, photodisinfection does not induce antimicrobial resistance formation. Carolyn Cross, CEO of Ondine, commented: "We continue to demonstrate, both clinically in hospitals across Canada and in the lab, that photodisinfection can provide a real alternative to topical antimicrobials which are no longer effective against an increasing number of pathogens. The evidence continues to show that photodisinfection destroys all types of pathogens including viruses, bacteria and fungi even those in biofilm, and we believe this technology can save millions of lives. The results of this study are particularly welcome as we prepare for our US Phase 3 trial in partnership with HCA Healthcare who are providing invaluable guidance and support." |
Posted at 09/11/2023 20:13 by z1co Beeks of ArabiaYou remind me of another troll that started to deramp CSFS at the beginning of the year when the CSFS share price was around 6.25p. He was also deramping the same way that you're doing ie share placing etc etc He eventually run off with his tail firmly stuck between his legs when the share price started to rise and it eventually reached 18p and that's exactly what will happen to you. These shares are poised to rerate massively near term. OBI will at least double over the next few months. Meanwhile CLCO will fall even more over the next few months. |
Posted at 07/11/2023 11:53 by bamboo2 Looking at the longer term share price, I wonder if the firm regrets listing on the UK AIM market?It's worth pointing out many other AIM share prices follow the same path. |
Posted at 01/11/2023 17:59 by z1co Worth mentioning again:Steriwave proven highly effective against XDR bacteria Ondine to present research demonstrating high efficacy against Extensively Drug-Resistant (XDR) bacteria at ICPIC 2023, Geneva Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) is presenting new research at the 2023 International Consortium on Prevention & Infection Control (ICPIC) in Geneva, demonstrating high efficacy of its patented photodisinfection technology against extensively drug-resistant (XDR) bacteria. Ondine is the global leader in developing photodisinfection-ba The study demonstrates that Ondine's Steriwave (TM) photodisinfection technology is highly effective (>99.99% kills in 20 seconds) against both moderately drug-resistant (MDR) and extensively drug-resistant (XDR) pathogens. Gram-negative bacteria, such as Escherichia coli, Pseudomonas aeruginosa, Enterobacter cloacae, and Klebsiella pneumoniae cause many serious healthcare-associate Antimicrobial resistance (AMR) poses an urgent global public health threat resulting in 1.27 million annual deaths worldwide, and is predicted to become one of the largest threats to human health in the coming years. ([i]) The emergence and worldwide spread of extensively drug-resistant (XDR) microbes is highly concerning, as infections caused by these pathogens are virtually untreatable because they are proving resistant to almost all approved antimicrobial agents. ([ii]) (, [iii]) Dr. Nicolas Loebel, Ondine's CTO and President, commented: "Overuse of antibiotics over decades has caused adaptation in many microbes, and we now see multidrug resistance (MDR) evolving into extensive drug resistance (XDR) in bacteria, rendering even the most powerful combination of drugs ineffective. We believe photodisinfection can play a significant role in cost-effectively combatting these drug-resistant pathogen and reducing global reliance on antibiotics. We know of no other antimicrobial that can match the performance, safety, and cost benefits of photodisinfection." |
Posted at 24/10/2023 07:00 by z1co Another positive update from Ondine Biomedical Inc (LON: OBI). The Steriwave photodisinfection technology helped to reduce spine surgery infection rates by two-thirds at Vancouver General Hospital. This is based on an eight-year study and there was a net annual cost saving of C$2.5m. The share price improved 15% to 11.5p. |
Posted at 18/10/2023 10:44 by bamboo2 Z1, you make good points, but personally I wouldn't bother replying to these short one-liners. Once this gathers some momentum they'll move on.There looks to be plenty of news on the horizon. As the co moves from trials to regular use of the product in hospitals, the empirical evidence will help fuel the clinical story. This was the key news in my starting a position here... RNS Non-Regulatory TIDMOBI Ondine Biomedical Inc. 09 October 2023 9 October 2023 ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine" or the "Company") Hospital to adopt Steriwave as standard-of-care Penticton Regional Hospital (PRH), located in the Okanagan area of British Columbia, has committed to implementing Canadian life sciences company Ondine Biomedical's (LON: OBI) Steriwave(R) nasal photodisinfection technology as standard-of-care for patients undergoing orthopedic surgery. Penticton Regional Hospital, affiliated with UBC Faculty of Medicine, currently undertakes approximately 900 orthopedic surgeries annually. The PRH team has selected Steriwave as a highly effective method of preventing hospital-acquired infections (HAIs) following surgery. This is particularly important due to growing concern about antimicrobial resistance (AMR), as hospitals must adapt their protocols to combat the rapid rise of drug-resistant pathogens. One in nine hospital patients in Canada gets a healthcare-associate |
Posted at 18/10/2023 06:50 by bamboo2 Ondine Biomedical Inc. Steriwave shown to reduce resistant bacteria18/10/2023 7:00am RNS Non-Regulatory TIDMOBI Ondine Biomedical Inc. 18 October 2023 18 October 2023 ONDINE BIOMEDICAL INC. ("Ondine Biomedical", "Ondine" or the "Company") Steriwave shown to reduce resistant bacteria by >99.9% -- New research presented by Ondine shows that Steriwave photodisinfection reduces antibiotic-resistant bacteria by more than 99.9% without generating resistance. -- The research suggests that photodisinfection is a viable alternative to antibiotics. Canadian life sciences company Ondine Biomedical Inc. (LON: OBI) is today presenting new research showing that Steriwave (R) photodisinfection reduced antibiotic-resistant bacteria by more than 99.9%. The in vitro study, which is being presented today at the IP2023 Annual conference taking place in Liverpool 17-19 October 2023, indicates that photodisinfection is likely to play an important role in strategies for combatting antimicrobial resistance (AMR). The controlled study evaluated the efficacy of Ondine's Steriwave (R) photodisinfection against Gram-negative and Gram-positive multidrug-resistant (MDR) and extensively drug-resistant (XDR) bacteria with novel antibiotic resistance factors. All of the bacterial strains used in the study exhibited resistance against some of the most commonly prescribed antibiotic classes, including penicillin, tetracyclines, quinolones and carbapenems. The results of the study showed that treatment with photodisinfection resulted in >99.9% reduction of viable bacteria compared to the control, regardless of the antibiotic susceptibility of the bacteria. The authors concluded that photodisinfection is likely an important adjunct to AMR strategies in the future and that further clinical studies are warranted. Antimicrobial resistance (AMR) remains a major public health concern, causing 33,000 deaths in Europe annually ([1]) which is projected to rise to over 10 million globally by 2050. ([2]) There are widespread multidrug-resistant (MDR) and extensively drug-resistant (XDR) infections across the world which are mainly caused by Gram-negative bacteria including Enterobacteriaceae and P. aeruginosa AMR bacteria ([3]) (, [4]) and Gram-positive bacteria such as Staphylococcus spp. ([5]) Steriwave has been found to be highly effective against all these pathogens. Photodisinfection uses a photosensitizer and a specific wavelength of light to trigger photochemical reactions that produce reactive oxygen species. These reactive oxygen species are lethal to a broad spectrum of microbes, including bacteria, fungi, and viruses. Importantly, photodisinfection does not induce antimicrobial resistance formation. Carolyn Cross, CEO of Ondine, commented: "We continue to demonstrate, both clinically in hospitals across Canada and in the lab, that photodisinfection can provide a real alternative to topical antimicrobials which are no longer effective against an increasing number of pathogens. The evidence continues to show that photodisinfection destroys all types of pathogens including viruses, bacteria and fungi even those in biofilm, and we believe this technology can save millions of lives. The results of this study are particularly welcome as we prepare for our US Phase 3 trial in partnership with HCA Healthcare who are providing invaluable guidance and support." The poster presentation, "Antimicrobial Photodynamic Therapy Against Extensively Drug-Resistant (XDR) Gram Negative Isolates With Novel Antibiotic Resistance Factors", is being presented at IP2023 between 1:10pm and 2:40pm (BST) on 18 October 2023. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
|
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions Support: +44 (0) 203 8794 460 | support@advfn.com |
| ADVFN UK Investors Hub ADVFN Italy ADVFN Australia ADVFN Brazil |
| ADVFN Canada ADVFN Germany ADVFN Japan ADVFN Mexico |
| ADVFN France ADVFN US ADVFN Korea |
